← Russell 3000 cross-section

PLX Protalix BioTherapeutics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-12, not restated
Healthcare

Scale

Market cap
$207m
Revenue TTM
$81m
Net income TTM
$19m
Free cash flow
$8m
Composite score
79.8
Sector rank
#2854

Valuation

P / E
11.0
EV / EBITDA
7.2
EV / sales
2.2
FCF yield
3.70%
Earnings yield vs 10-yr
4.38pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
23.5%
EBITDA margin
30.8%
ROE
26.5%
ROIC
53.0%
Revenue growth
30.1%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Chiesi is required to make payments to Protalix Ltd. ranging from 15% to 35% of its net sales under the Chiesi Ex-US Agreement, depending on the amount of annual sales, subject to certain terms and conditions, as consideration for product supply. Chiesi is required to make payments to Protalix Ltd. ranging from 15% to 40% of its net sales under the Chiesi US Agreement, depending on the amount of annual sales, subject to certain terms and conditions, as consideration for product supply. …Protalix BioTherapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-12

Read the full passage →